Zenas Biopharma says it’s on track to submit applications this year in the U.S. and the European Union seeking approval of its experimental injection therapy obexelimab for treating immunoglobulin G4-related disease (IgG4-RD). In fact, the developer noted that it intends to file a biologics license application to the…
Rituximab appears to control immunoglobulin G4-related disease (IgG4-RD) about as well as glucocorticoids but allows patients to use lower doses of this type of corticosteroid — a class of steroid hormones — overall, which may prevent serious side effects, according to a large real-world study in Europe. “Our…
In rare cases where IgG4-related disease (IgG4-RD) affects the pericardium, surgery to remove all or part of this sac surrounding the heart is usually necessary to control the disease, according to a study of 5 patients in the U.S. “Medical therapy alone is often inadequate, and [surgery] remains the…
Get regular updates to your inbox.
